Trial Profile
Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2019
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- 16 Nov 2019 Status changed from active, no longer recruiting to completed.
- 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Oct 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2018.